Palatin Technologies

PTN · NYSE American

$5.52−$0.47 (−7.85%)TodayMarket closed · Oct 20, 4:34 PM ET

Prev close $5.99

PTN analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $54.57 (+888.6% upside)

Low: $47.97
Now: $5.52
High: $63.00

Upgrades and downgrades

The latest rating actions, newest first

PTN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Laidlaw & Co.	Dec 12, 2025	Initiates	Buy	$60.00	7%

The case for and against

Updated May 8, 2025

Bull case

Palatin Technologies Inc. is poised for growth as it transitions focus toward the obesity market, supported by promising data demonstrating significant weight loss effects from its candidate PL7737 in preclinical studies. The initial addressable market size for its therapies suggests an attractive valuation, reinforcing the financial prospects associated with these developments. Furthermore, positive Phase 2 study results could validate the synergy of bremelanotide with GLP-1 receptor agonists, positioning Palatin favorably within a competitive therapeutic space with substantial unmet medical needs.

Bear case

Palatin Technologies Inc faces significant challenges that may negatively impact its stock outlook, primarily due to the risk of failed or inconclusive clinical trials, which could hinder the progression of its drug candidates. Additionally, the company's ability to secure adequate funding remains uncertain, which is crucial for advancing its development pipeline. These fundamental concerns regarding clinical efficacy and financial stability create a precarious environment for the company's long-term growth potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.